Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?

Abstract

Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.

Cite this paper

@article{Biagio2014WhichPH, title={Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?}, author={A Di Biagio and Roberta Prinapori and Lucia Taramasso and Giulia Gustinetti and Laura Sticchi and Bianca Bruzzone and Claudio Viscoli}, journal={Recent patents on anti-infective drug discovery}, year={2014}, volume={9 1}, pages={41-51} }